Abstract

591 Background: Entinostat (ENT) is an oral, class 1 isoform selective histone deacetylase inhibitor shown to extend progression free and overall survival when combined with exemestane (EXE) in post-menopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC) who have progressed on prior non-steroidal aromatase inhibitors (Yardley et al; JCO 31:2128;2013). Based on these results ENT was granted Breakthrough Therapy designation by the FDA for this indication. This Phase 1 study evaluated the effect of food on ENT PK in patients (pts) with MBC and advanced non-small cell lung cancer (NSCLC). Methods: A total of 17 pts (14 postmenopausal ER+ MBC and 3 NSCLC) were randomized 1:1 to receive ENT 10 mg administered Day 1 and 15 of a 28 day lead-in cycle, fasting and with food. Pts randomized to ENT with food on Cycle 1 Day 1 (C1D1) received ENT fasted on Cycle 1 Day 15 (C1D15); pts randomized to ENT fasted on C1D1 received ENT with food on C1D15. Blood samples were obtained pre-dose C1D1...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.